With 
JYNT attracting one of the most viewership count for our trades since it was first highlighted in January 2021, I will be doing a periodic update to JYNT ahead of its earnings on 11th March 2021.
JYNT shares soar further by +4.02% at the close of yesterday’s session, closing at $41.41. This totals up a gain of +51.80% since JYNT was first highlighted in January. The latest price action reflects a Bearish Shooting Star candlestick signal, on low transactional volume. This shall bring caution to existing investors of imminent consolidation, or price correction in its recent rally.
With implied volatility incrementing by a further +5% to a range of 22.10/DAY, it is plausible to seeJYNT breaking out further from its current consolidated price action ahead of its earnings on 11th March 2021.
JYNT develops, owns, operates, supports, and manages chiropractic clinics in the United States
JYNT attracting one of the most viewership count for our trades since it was first highlighted in January 2021, I will be doing a periodic update to JYNT ahead of its earnings on 11th March 2021.JYNT shares soar further by +4.02% at the close of yesterday’s session, closing at $41.41. This totals up a gain of +51.80% since JYNT was first highlighted in January. The latest price action reflects a Bearish Shooting Star candlestick signal, on low transactional volume. This shall bring caution to existing investors of imminent consolidation, or price correction in its recent rally.With implied volatility incrementing by a further +5% to a range of 22.10/DAY, it is plausible to see
JYNT breaking out further from its current consolidated price action ahead of its earnings on 11th March 2021.JYNT develops, owns, operates, supports, and manages chiropractic clinics in the United States
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.